Zydus Lifesciences

ZYDUSLIFE.NS

Ahmedabad, India· Est. 1952

zyduslife.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ZYDUSLIFE.NS · Stock Price

INR 940.30+66.60 (+7.62%)

Market Cap: $10.0B

Historical price data

Market Cap: $10.0BPipeline: 23 drugs (6 Phase 3)Patents: 10Founded: 1952Employees: 29000+HQ: Ahmedabad, India

Sector Ranking#14 in Small Molecule Drugs #8 in Biologics / Biosimilars

Overview

Zydus Lifesciences is a mission-driven global pharmaceutical company dedicated to creating healthier, happier communities worldwide. Its strategy is built on a dual engine of deep expertise in complex generics and a robust innovation pipeline in novel chemical entities (NCEs), biologics, and vaccines. Key achievements include launching Lipaglyn, the first NCE from an Indian research pipeline, and pioneering biosimilars like Exemptia (adalimumab), while maintaining strong financial growth and a vast commercial footprint.

Cardio-MetabolicInflammation and ImmunologyNeurosciencesOncologyRare DiseasesInfectious Diseases

Technology Platform

An integrated multi-platform ecosystem encompassing complex generics & specialty formulations, novel chemical entity (NCE) discovery, biologics & biosimilars development, and vaccines innovation, supported by vertical manufacturing integration.

Pipeline

23 drugs in pipeline6 in Phase 3

Drug	Indication	Stage
Saroglitazar	NAFLD	Approved
Desidustat	Chronic Kidney Diseases	Approved
Desidustat Oral Tablet + Epoetin Alfa	Chronic Kidney Disease Stage 5 on Dialysis	Phase 3
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel + DUAC®...	Acne Vulgaris	Phase 3
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)	Metastatic Breast Cancer	Phase 3

Funding History

IPOUndisclosedUndisclosedJun 15, 2000

FDA Approved Drugs

DAPSONEANDAFeb 26, 2026

IVERMECTINANDAFeb 26, 2026

BOSENTANANDAFeb 17, 2026

Opportunities

Zydus is leveraged to capitalize on the global shift towards complex generics and biosimilars, the massive unmet need in metabolic diseases like NASH, and growing vaccine demand in emerging markets.

Its integrated model and proven innovation capability provide multiple avenues for sustained growth.

Risk Factors

Key risks include regulatory compliance challenges across its global manufacturing network, clinical trial failures or delays in its innovative pipeline (notably Saroglitazar for NASH), and intense pricing pressure in the global generics market.

Geopolitical and currency volatility also pose threats to its international operations.

Competitive Landscape

Zydus competes with large Indian generics firms (Sun Pharma, Dr. Reddy's) domestically, global generics/biosimilar players (Teva, Sandoz) internationally, and large biopharma in innovation. Its competitive edge lies in its vertical integration, focus on high-barrier complex products, and a demonstrated track record of translating R&D into commercial novel therapies and biosimilars.